Beclometasone/formoterol/glycopyrronium triple therapy protects COPD patients from mortality and cardiovascular events: insights from a Bayesian analysis (ERS 2026) - May 30, 2026 - Abstract #PA5824; Pres time: Sep 8, 2026; 12:30 PM - 02:00 PM; Location: PS-13; Board Number: 16; "Very strong evidence supported reduced risk of MACE (LogOR -0.41, 95%CI -0.81 – -0.020; BF 45.52) and IHD (LogOR -0.51, 95%CI -0.99 – -0.04; BF 52.63). Detailed information is shown in Figure 1.ConclusionBDP/FF/G shows strong to very strong evidence of reducing all-cause mortality, MACE, and IHD vs. BT, supporting its protective survival and cardiovascular benefits in COPD."
Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Heart Failure • Immunology • Respiratory Diseases
|
|
P. Rogliani; Italy; L. Calzetta; Italy
|